Electroacupuncture Regulation of Immune Cells in Herpes Zoster
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age50-70
SponsorFirst People's Hospital of Hangzhou
About this trial
Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females. HZ affects patients' physical health, mental well-being, and quality of life. The immune system is critical in HZ pathogenesis. Studies show acupuncture relieves pain, modulates immunity, and may lower postherpetic neuralgia (PHN) risk. However, evidence is limited on whether electroacupuncture (EA) alleviates HZ by modulating immune cells. Using mass cytometry (CyTOF), this study will analyze peripheral immune cell changes pre- and post-EA to explore its regulatory effects on HZ immunity. This study will recruit HZ patients and healthy controls (HC), dividing patients into medication-only and medication+EA groups to assess EA's potential immunomodulatory effects in HZ treatment.
Eligibility criteria
Qualifiers
Meets HZ diagnostic criteria;
Female, aged between 50 and 70 years;
Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;
Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;
Disqualifiers
Special types of herpes zoster, including ophthalmic, otic, visceral, meningeal herpes zoster, and zoster sine herpete;
Women who are planning to conceive, pregnant, or breastfeeding;
Patients with severe primary diseases of the circulatory, respiratory, or endocrine systems, or systemic failure;
Patients with bleeding tendencies;
Trial design
Treatments tested in this trial
- Drug
- Electroacupuncture
Treatment groups
8 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov